✦ LIBER ✦

An inventory of shedding data from clinical gene therapy trials

✍ Scribed by Ellen A. M. Schenk-Braat; Marjolein M. K. B. van Mierlo; Gerard Wagemaker; Chris H. Bangma; Leonie C. M. Kaptein

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 172 KB
Volume: 9
Category: Article
ISSN: 1099-498X
DOI: 10.1002/jgm.1096

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Viruses are the most commonly used vectors for clinical gene therapy. The risk of dissemination of a viral vector into the environment via excreta from the treated patient, a phenomenon called shedding, is a major safety concern for the environment. Despite the significant number of clinical gene therapy trials that have been conducted worldwide, there is currently no overview of actual shedding data available. In this article, an inventory of shedding data obtained from a total of 100 publications on clinical gene therapy trials using retroviral, adenoviral, adeno‐associated viral and pox viral vectors is presented. In addition, the experimental set‐up for shedding analysis including the assays used and biological materials tested is summarized. The collected data based on the analysis of 1619 patients in total demonstrate that shedding of these vectors occurs in practice, mainly determined by the type of vector and the route of vector administration. Due to the use of non‐quantitative assays, the lack of information on assay sensitivity in most publications, and the fact that assay sensitivity is expressed in various ways, general conclusions cannot be made as to the level of vector shedding. The evaluation of the potential impact and consequences of the observations is complicated by the high degree of variety in the experimental design of shedding analysis between trials. This inventory can be supportive to clinical gene therapy investigators for the establishment of an evidence‐based risk assessment to be included in a clinical protocol application, as well as to national regulatory authorities for the ongoing development of regulatory guidelines regarding gene therapy. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

ANALYSIS OF MULTIPLE FAILURE TIME DATA F

ANALYSIS OF MULTIPLE FAILURE TIME DATA FROM AN AIDS CLINICAL TRIAL

✍ DIANNE M. FINKELSTEIN; DAVID A. SCHOENFELD; EVA STAMENOVIC 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

The primary endpoint of AIDS prophylaxis trials is the occurrence of opportunistic infections. While the treatments are not expected to have an effect on the underlying HIV disease, an effect of treatments on mortality cannot be ruled out. Therefore, the primary analysis of these trials must be base

French gene therapy group reports on the

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position statement from the European Society of Gene Therapy (ESGT)

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

## Position statement from the European Society of Gene Therapy (ESGT) Background News of a serious adverse event in a clinical trial of gene therapy for inherited, X chromosome-linked Severe Combined Immunodeficiency (X-SCID) was made public on October 2, 2002, by the group of French scientists p

Analysis of multiple failure time data f

Analysis of multiple failure time data from an AIDS clinical trial by Dianne M. Finkelstein, David A. Schoenfeld and Eva Stamenovic, Statistics in Medicine, 16, 951–961 (1997)

✍ Cédric Mahé 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 3 views

have presented recently an interesting paper on the way to analyse AIDS clinical trials when we have a combined endpoint of infection recurrences and death. They use one of the most famous multivariate generalizations of the proportional hazards model: the model of Wei, Lin and Weissfield (hereafter

Evidence of radiographic benefit of trea

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study

✍ J. S. Smolen; C. Han; M. Bala; R. N. Maini; J. R. Kalden; D. van der Heijde; F. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

An index of the three core data set pati

An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial

✍ T. Pincus; V. Strand; G. Koch; I. Amara; B. Crawford; F. Wolfe; S. Cohen; D. Fel 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 3 views